Evidence map›Paper›PMID 35252031›Full record

ArticleFrontiers in cellular and infection microbiology2022

Rapid Visual Detection of Hepatitis C Virus Using Reverse Transcription Recombinase-Aided Amplification-Lateral Flow Dipstick.

Haili Wang, Yuhang Zhang, Jingming Zhou, Ming Li, Yumei Chen, Yankai Liu, Hongliang Liu, Peiyang Ding, Chao Liang, Xifang Zhu and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. A review of historical landmarks and pioneering technologies for the diagnosis of Hepatitis C Virus (HCV).European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Current advances in Hepatitis C diagnostics.Journal of biological engineering · 2024
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Haili WangSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Yuhang ZhangCollege of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.
Jingming ZhouSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Ming LiHenan Key Laboratory of Population Defects Prevention, National Health Commission Key Laboratory of Birth Defects Prevention, Henan Institute of Reproduction Health Science and Technology, Zhengzhou, China.
Yumei ChenSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Yankai LiuSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Hongliang LiuSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Peiyang DingSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Chao LiangSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Xifang ZhuSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Ying ZhangSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Cheng XinSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Gaiping ZhangSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Aiping WangSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Zhengzhou University · CNHenan Agricultural University · CNNational Health and Family Planning Commission · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) infection is a global public health threat. Reaching the World Health Organization's objective for eliminating viral hepatitis by 2030 will require a precise disease diagnosis. While immunoassays and qPCR play a significant role in detecting HCV, rapid and accurate point-of-care testing is important for pathogen identification. This study establishes a reverse transcription recombinase-aided amplification-lateral flow dipstick (RT-RAA-LFD) assay to detect HCV. The intact workflow was completed within 30 min, and the detection limit for synthesized C/E1 plasmid gene-containing plasmid was 10 copies/μl. In addition, the test showed good specificity, with no cross-reactivity observed for hepatitis A virus, hepatitis B virus, HIV, syphilis, and human papillomavirus virus. Using extracted RNAs from 46 anti-HCV antibody-positive samples, RT-RAA-LFD showed 100% positive and negative concordance rates with qPCR. In summary, the RT-RAA-LFD assay established in this study is suitable for the rapid clinical detection of HCV at the community level and in remote areas.

Indexed as

Hepatitis CReverse TranscriptionHepacivirusHumansNucleic Acid Amplification TechniquesRecombinasesSensitivity and SpecificityRecombinaseshepatitis C viruslateral flow dipsticknucleic acid detectionpoint-of-care testingrecombinase-aided amplification

Identifiers

PMID35252031
PMCPMC8892114
OpenAlexW4212960482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.